SYSTEM PROBLEMS:
We are currently experiencing technical problems with content and functionality requiring a login.
We apologize for the inconvience.
Showing session: reset
I WANT A NEW DRUG
- Sort by:
|
<< first | < prev
page:
of 1
|
records per page:
next > | last >>
|
| pages: 1
|
presentations:
1 to
7 of
7
|
THEMED DISCUSSION LEADER
Karl Salzwedel
National Institutes of Health, Bethesda , MD, USA
NOVEL HIV PI WITH HIGH RESISTANCE BARRIER AND POTENTIAL FOR UNBOOSTED QD ORAL DOSING
John O Link
Gilead Sciences, Foster City, CA, USA
NOVEL NON-CATALYTIC SITE INTEGRASE INHIBITOR WITH IMPROVED RESISTANCE PROFILE
Michael Lloyd Mitchell
Gilead Sciences, Foster City, CA, USA
MK-8591 CONCENTRATIONS AT SITES OF HIV TRANSMISSION AND REPLICATION
Jay Grobler
Merck & Co, West Point, PA, USA
GS-9131 IS A NOVEL NRTI WITH ACTIVITY AGAINST NRTI-RESISTANT HIV-1
Kirsten Lofgren White
Gilead, Foster City, CA, USA
PRO140 Single-Agent Maintenance Therapy for HIV-1 Infection: A 2-Year Update
Kush Dhody
Amarex Clinical Research, LLC, Germantown, MD, USA
|
<< first | < prev
page:
of 1
|
records per page:
next > | last >>
|
| pages: 1
|
presentations:
1 to
7 of
7
|
